BRAIN Biotech Past Earnings Performance
Past criteria checks 0/6
BRAIN Biotech has been growing earnings at an average annual rate of 6.9%, while the Chemicals industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 9.5% per year.
Key information
6.9%
Earnings growth rate
12.0%
EPS growth rate
| Chemicals Industry Growth | 12.4% |
| Revenue growth rate | 9.5% |
| Return on equity | -40.5% |
| Net Margin | -15.2% |
| Next Earnings Update | 28 May 2024 |
Recent past performance updates
Recent updates
BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate
Apr 19
BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable
Mar 28Is BRAIN Biotech (ETR:BNN) A Risky Investment?
Feb 16Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt
Sep 13Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like
Mar 21Is B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Weighed On By Its Debt Load?
Feb 14When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven?
Jan 18How Much Did B.R.A.I.N. Biotechnology Research and Information Network's(ETR:BNN) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 31
Are Institutions Heavily Invested In B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shares?
Dec 10Should You Investigate B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) At €7.30?
Nov 17Revenue & Expenses BreakdownBeta
How BRAIN Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 55 | -8 | 24 | 0 |
| 30 Sep 23 | 56 | -8 | 23 | 0 |
| 30 Jun 23 | 55 | -7 | 24 | 0 |
| 31 Mar 23 | 54 | -7 | 24 | 0 |
| 31 Dec 22 | 54 | -7 | 24 | 0 |
| 30 Sep 22 | 50 | -7 | 23 | 0 |
| 30 Jun 22 | 48 | -8 | 22 | 0 |
| 31 Mar 22 | 44 | -8 | 21 | 0 |
| 31 Dec 21 | 41 | -4 | 21 | 0 |
| 30 Sep 21 | 39 | -5 | 21 | 0 |
| 30 Jun 21 | 37 | -6 | 20 | 0 |
| 31 Mar 21 | 37 | -6 | 20 | 0 |
| 31 Dec 20 | 37 | -11 | 19 | 0 |
| 30 Sep 20 | 39 | -10 | 19 | 0 |
| 30 Jun 20 | 41 | -9 | 20 | 0 |
| 31 Mar 20 | 41 | -12 | 19 | 0 |
| 31 Dec 19 | 41 | -12 | 19 | 0 |
| 30 Sep 19 | 40 | -11 | 19 | 0 |
| 30 Jun 19 | 39 | -9 | 19 | 0 |
| 31 Mar 19 | 37 | -7 | 18 | 0 |
| 31 Dec 18 | 33 | -7 | 17 | 0 |
| 30 Sep 18 | 29 | -8 | 16 | 0 |
| 30 Jun 18 | 27 | -9 | 18 | 0 |
| 31 Mar 18 | 25 | -8 | 17 | 0 |
| 31 Dec 17 | 26 | -7 | 15 | 0 |
| 30 Sep 17 | 26 | -10 | 18 | 0 |
| 30 Jun 17 | 26 | -14 | 19 | 0 |
| 31 Mar 17 | 26 | -14 | 19 | 0 |
| 31 Dec 16 | 25 | -17 | 22 | 0 |
| 30 Sep 16 | 25 | -15 | 19 | 0 |
| 30 Jun 16 | 24 | -10 | 14 | 0 |
| 31 Mar 16 | 24 | -9 | 13 | 0 |
| 31 Dec 15 | 24 | -7 | 13 | 0 |
| 30 Sep 15 | 24 | -6 | 12 | 0 |
| 30 Sep 14 | 13 | -5 | 9 | 0 |
| 30 Sep 13 | 10 | -4 | 6 | 0 |
Quality Earnings: BNN is currently unprofitable.
Growing Profit Margin: BNN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BNN is unprofitable, but has reduced losses over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare BNN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNN is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-19.4%).
Return on Equity
High ROE: BNN has a negative Return on Equity (-40.47%), as it is currently unprofitable.